Lonidamine in metastatic breast cancer

Riccardo Rosso, Domenico Amoroso, Giovanni Gardin, Loredana Miglietta, Tiziana Guido, Maurizio Pace, Lazzaro Repetto, Paolo Pronzato

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Lonidamine belongs to a new class of antineoplastics agents, since it does interfere with cell energy processes. When administered as single agent in metastatic breast cancer, it produces moderate therapeutic effects. The pattern of toxicity includes myalgias, asthenia, testicular pain, and gastrointestinal discomfort. No myelosuppression was demonstrated in phase I-II studies. Since the peculiar mechanism of action and side effects are not overlapping with those of standard chemotherapeutic agents, combination of lonidamine with chemotherapy is currently under investigation in advanced breast cancer. Moreover, the potentiation of radiotherapy by lonidamine could be of interest in palliating symptomatic lesions from breast cancer.

Original languageEnglish
Pages (from-to)62-65
Number of pages4
JournalSeminars in Oncology
Volume18
Issue number2 SUPPL. 4
Publication statusPublished - 1991

Fingerprint

Breast Neoplasms
Asthenia
Myalgia
Therapeutic Uses
Antineoplastic Agents
Radiotherapy
Drug Therapy
Pain
lonidamine

ASJC Scopus subject areas

  • Oncology

Cite this

Rosso, R., Amoroso, D., Gardin, G., Miglietta, L., Guido, T., Pace, M., ... Pronzato, P. (1991). Lonidamine in metastatic breast cancer. Seminars in Oncology, 18(2 SUPPL. 4), 62-65.

Lonidamine in metastatic breast cancer. / Rosso, Riccardo; Amoroso, Domenico; Gardin, Giovanni; Miglietta, Loredana; Guido, Tiziana; Pace, Maurizio; Repetto, Lazzaro; Pronzato, Paolo.

In: Seminars in Oncology, Vol. 18, No. 2 SUPPL. 4, 1991, p. 62-65.

Research output: Contribution to journalArticle

Rosso, R, Amoroso, D, Gardin, G, Miglietta, L, Guido, T, Pace, M, Repetto, L & Pronzato, P 1991, 'Lonidamine in metastatic breast cancer', Seminars in Oncology, vol. 18, no. 2 SUPPL. 4, pp. 62-65.
Rosso R, Amoroso D, Gardin G, Miglietta L, Guido T, Pace M et al. Lonidamine in metastatic breast cancer. Seminars in Oncology. 1991;18(2 SUPPL. 4):62-65.
Rosso, Riccardo ; Amoroso, Domenico ; Gardin, Giovanni ; Miglietta, Loredana ; Guido, Tiziana ; Pace, Maurizio ; Repetto, Lazzaro ; Pronzato, Paolo. / Lonidamine in metastatic breast cancer. In: Seminars in Oncology. 1991 ; Vol. 18, No. 2 SUPPL. 4. pp. 62-65.
@article{03af20c063484268b2fdf7f2e588332c,
title = "Lonidamine in metastatic breast cancer",
abstract = "Lonidamine belongs to a new class of antineoplastics agents, since it does interfere with cell energy processes. When administered as single agent in metastatic breast cancer, it produces moderate therapeutic effects. The pattern of toxicity includes myalgias, asthenia, testicular pain, and gastrointestinal discomfort. No myelosuppression was demonstrated in phase I-II studies. Since the peculiar mechanism of action and side effects are not overlapping with those of standard chemotherapeutic agents, combination of lonidamine with chemotherapy is currently under investigation in advanced breast cancer. Moreover, the potentiation of radiotherapy by lonidamine could be of interest in palliating symptomatic lesions from breast cancer.",
author = "Riccardo Rosso and Domenico Amoroso and Giovanni Gardin and Loredana Miglietta and Tiziana Guido and Maurizio Pace and Lazzaro Repetto and Paolo Pronzato",
year = "1991",
language = "English",
volume = "18",
pages = "62--65",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "2 SUPPL. 4",

}

TY - JOUR

T1 - Lonidamine in metastatic breast cancer

AU - Rosso, Riccardo

AU - Amoroso, Domenico

AU - Gardin, Giovanni

AU - Miglietta, Loredana

AU - Guido, Tiziana

AU - Pace, Maurizio

AU - Repetto, Lazzaro

AU - Pronzato, Paolo

PY - 1991

Y1 - 1991

N2 - Lonidamine belongs to a new class of antineoplastics agents, since it does interfere with cell energy processes. When administered as single agent in metastatic breast cancer, it produces moderate therapeutic effects. The pattern of toxicity includes myalgias, asthenia, testicular pain, and gastrointestinal discomfort. No myelosuppression was demonstrated in phase I-II studies. Since the peculiar mechanism of action and side effects are not overlapping with those of standard chemotherapeutic agents, combination of lonidamine with chemotherapy is currently under investigation in advanced breast cancer. Moreover, the potentiation of radiotherapy by lonidamine could be of interest in palliating symptomatic lesions from breast cancer.

AB - Lonidamine belongs to a new class of antineoplastics agents, since it does interfere with cell energy processes. When administered as single agent in metastatic breast cancer, it produces moderate therapeutic effects. The pattern of toxicity includes myalgias, asthenia, testicular pain, and gastrointestinal discomfort. No myelosuppression was demonstrated in phase I-II studies. Since the peculiar mechanism of action and side effects are not overlapping with those of standard chemotherapeutic agents, combination of lonidamine with chemotherapy is currently under investigation in advanced breast cancer. Moreover, the potentiation of radiotherapy by lonidamine could be of interest in palliating symptomatic lesions from breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0025857427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025857427&partnerID=8YFLogxK

M3 - Article

C2 - 2031200

AN - SCOPUS:0025857427

VL - 18

SP - 62

EP - 65

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 2 SUPPL. 4

ER -